Qu Biologics is a biopharmaceutical company located in Vancouver, BC, Canada.
Qu Biologics is developing Site Specific Immunomodulators (SSIs), novel immunotherapies that are designed to stimulate an innate immune response to reverse the chronic inflammation underlying many conditions such as Crohn’s disease and ulcerative colitis.
Qu Biologics is conducting a clinical trial for patients with moderate-to-severe ulcerative colitis. We have had strong interest in this study and all spots for the first group of participants for this clinical trial have been filled. Enrollment of a second group of participants into this clinical trial is expected to begin in early 2017. If you are an adult living with active ulcerative colitis and are interested in joining the second group of the ulcerative colitis clinical trial, please email firstname.lastname@example.org to request to be added to the waitlist. You will be notified once recruitment for the second group begins.
Enrollment into the Crohn’s disease clinical trial has completed and we are no longer accepting new participants. Initial Week 8 and preliminary Week 16 results are now available here. If you are interested in receiving updates about a future clinical trial in Crohn’s disease involving Qu Biologics’ Site Specific Immunomodulators (SSIs), please email email@example.com indicating your request.
To send us an e-mail, please fill out the form below.
We appreciate your interest and will make every effort to reply to your message as soon as possible.